长春高新：子公司金赛药业伏欣奇拜单抗临床试验申请获受理

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Jinsai Pharmaceutical, has received acceptance from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection for domestic production [1] Group 1: Product Information - Fuxin Qibai monoclonal antibody is a fully human anti-IL-1β monoclonal antibody that specifically blocks the binding of IL-1β to its receptor, thereby inhibiting the activation of downstream signaling pathways [1] - The drug is primarily used for the treatment of non-infectious uveitis, and there are currently no similar drugs approved for the same disease area in both domestic and international markets [1]